Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul;7(6):733-734.
doi: 10.1177/2050640619851683. Epub 2019 Jun 21.

Biologics' switching: new insights toward establishing practice norms

Hussein Mahagna  1   2 , Shomron Ben-Horin  1   2
Affiliations
Editorial

Biologics' switching: new insights toward establishing practice norms

Hussein Mahagna et al. United European Gastroenterol J. 2019 Jul.
No abstract available

PubMed Disclaimer

References

    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721. - PubMed
    1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699–710. - PubMed
    1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383–1395. - PubMed
    1. Liefferinckx C, Verstockt, Gils A, et al. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterol J. Epub ahead of print 24 March 2019. DOI: 10.1177/2050640619841538. - PMC - PubMed
    1. Ben-Horin S, Ungar B, Kopylov U, et al. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Aliment Pharmacol Ther 2018; 47: 1117–1125. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources